Differential regulation of microtubule-associated protein 1B (MAP1B) in rat CNS and PNS during development

MAP1B is a major cytoskeletal protein in growing axons and is strongly regulated during brain development. The present studies compare the expression of MAP1B mRNA, the protein, and its phosphorylated isoform in spinal cord and dorsal root ganglia (DRGs) with brain. In spinal cord and brain, MAP1B mRNA levels were highest in early stages of development, decreased several fold during postnatal development, and remained low in adults. In contrast, there were no significant changes of MAP1B mRNA levels during development of DRG and they remained high in adults. The levels of MAP1B protein decreased in brain and spinal cord in parallel with the changes of their mRNA. The protein levels in DRG remained relatively high but declined in the sciatic nerve. Phosphorylated MAP1B was expressed in high levels during the early stages of development in brain, spinal cord, and sciatic nerve and decreased rapidly to undetectable levels postnatally except for sciatic nerve where it remained detectable. Immunohistochemical analysis showed that phosphorylated MAP1B was absent from DRG cell bodies at all stages but was present in axons of DRG and motor neurons in both spinal cord and sciatic nerve. Immunostaining also confirmed Western blot analysis indicating that MAP1B was initially abundant within the spinal cord but was at later stages present only in motor neurons and the central processes of DRG neurons. These results reflect differential distribution of MAP1B isoforms at different stages of development and in different regions of the nervous system. J. Neurosci. Res. 49:319–332, 1997. © 1997 Wiley-Liss, Inc.     

Lack of central sprouting of primary afferent fibers after ricin deafferentation

A new deafferentation technique, the application of ricin to peripheral nerves, was used to test for collateral sprouting of undamaged primary afferent fibers within the adult mammalian spinal cord dorsal horn. The right sciatic nerves in rats were injected with ricin 14 to 57 days prior to bilateral labelling of dorsal rootlets with horseradish peroxidase. To equate the number of surviving dorsal root fibers on the two sides, the left sciatic nerves were injected 5 days prior to labelling. In each animal, horseradish peroxidase was applied to a bilateral pair of lumbar or low thoracic dorsal rootlets 18 hours prior to sacrifice to test for sprouting by labelling primary afferent fibers and terminals in the right (experimental) and left (control) dorsal horns. Although there is overlap of degenerated and intact primary afferent fields in this preparation, a postulated precondition for sprouting (Murray and Goldberger: J. Neurosci. 6:3205-3217, '86), we found no evidence for sprouting of undamaged, myelinated afferent fibers in the experimental dorsal horns. The pattern of labelling was symmetrical in all animals, and the density of labelling was not consistently greater on the experimental side. These results support the conclusions of Rodin et al. (J. Comp. Neurol. 215:187-198, '83) and Rodin and Kruger (Somatosens. Res. 2:171-192, '84), who also found no sprouting in the rat's dorsal horn after surgical deafferentation, and do not support the assertion that the difference between the results of those studies and earlier studies in cats was due to a lack of overlap of degenerated and intact dorsal roots in the rat.     

黄芩苷对糖尿病患者红细胞醛糖还原酶活性及周围神经传导速度的影响

观察中药黄芩苷对糖尿病患者醛糖还原酶 (AR)活性抑制作用及对糖尿病神经病变影响。 37例糖尿病神经病变患者随机分为对照组 (18例 ,常规治疗 )和治疗组 (19例 ,常规治疗 黄芩苷 ) ,疗程 4周 ,治疗前后分别测定红细胞AR ,运动、感觉神经传导速度 ,膀胱残余尿量。上述指标治疗前二组相似 ,治疗后治疗组AR活性受到抑制 ,明显低于对照组 ,运动、感觉神经传导速度的改善明显高于对照 ,膀胱残余尿量亦显著少于对照组。黄芩苷可明显抑制AR活性 ,改善神经病变的指标 ,有助于糖尿病神经病变的治疗。     

Chemical characterization of substance P-like immunoreactivity in primary afferent neurones

Substance P-like immunoreactivity (SPLI) in rat dorsal root ganglia and dorsal spinal cord was characterized by high-performance liquid chromatography followed by radioimmunoassay. In spinal cord and ganglia, respectively, 87% and 64% of SPLI eluted with authentic SP. The remainder of the SPLI in ganglia eluted as a single peak which did not represent the sulphoxide of SP or any of its C-terminal fragments.     

Preemptive analgesic effects of low-dose ketamine on growth-associated protein expression in dorsal root ganglion of chronic constriction injury model rats★

BACKGROUND： Ketamine is a noncompetitive N-methyl-D-aspartate （NMDA） receptor antagonists and plays an important role in the treatment of pain. OBJECTIVE： To analyze the preemptive analgesic effects of different doses of ketamine on growth-associated protein-43 （GAP43） expression in dorsal root ganglion in a rat model of chronic sciatic nerve constricted injury, and to study the differences between high-dose and low-dose ketamine DESIGN： Randomized controlled animal study. SETTING： Medical College of Shantou University. MATERIALS： Thirty-five adult male Sprague Dawley rats were provided by the Experimental Animal Center of Guangzhou University of Traditional Chinese Medicine. Ketamine hydrochloride injection was provided by Hengrui Pharmaceutical Co., Ltd., Jiangsu. METHODS： This study was performed at the Immunological Laboratory, Medical College of Shantou University from September to December 2006. Model of chronic sciatic nerve constricted injury： after anesthesia, the right sciatic nerve was exposed and ligated l-cm distal to the ischiadic tuberosity with a No. 3-0 cat gut suture. Grouping and intervention： 35 rats were randomly divided into 4 groups： normal control group （n = 5）, chronic constriction injury （CCI） group （n = 10）, low-dose ketamine group （n = 10）, and high-dose ketamine group （n = 10）. Rats in the normal control group did not undergo any surgery or drug intervention. Rats in the CCI group received intraperitoneal injection of saline （1 mL）, and their sciatic nerves were ligated after 10 minutes. Rats in the low-dose ketamine group underwent intraperitoneal injection of ketamine （25 mg/kg） 10 minutes prior to ligation of sciatic nerve; while, rats in the high-dose ketamine group were given intraperitoneal injection of ketamine （50 mg/kg） 10 minutes prior to ligation of sciatic nerve. On the third and the seventh days after surgery, dorsal root ganglion were resected from the sciatic nerve and cut into sections. MAIN OUTCOME MEASURES：     

Dendritic distribution of motoneurons innervating the three heads of the trapezius muscle in the cat

The organization of the nuclei and dendritic architecture of motoneurons innervating the three heads of the trapezius muscle, clavotrapezius (CT), acromiotrapezius (AT), and spinotrapezius (ST), have been examined by using intracellular staining techniques. CT, AT, and ST motoneurons were found in the spinal accessory nucleus and were arranged in three overlapping subnuclei. CT motoneurons were primarily found in C2 and C3. In contrast, most AT motoneurons were found in C3, C4, and C5 and ST motoneurons were found in C4, C5, and the rostral parts of C6. Most dendrites of CT motoneurons, located in rostral C2, extended dorsally and many of these dendrites spread medially and laterally to encompass all of lamina VIII and the dorsolateral part of lamina VII. When viewed in the horizontal plane these motoneurons had a stellate appearance. The dendritic tree structure of CT motoneurons changed abruptly between rostral C2 and mid-C2. The majority of dendrites of CT motoneurons located in the central and caudal parts of C2 projected rostrally and caudally to form a complex bundle of dendrites in the motoneuron nucleus. Small numbers of dendrites were also found ventromedial and dorsal to the soma. The dendritic trees of CT motoneurons in C3 and C4 and AT and ST motoneurons located in C4 and the rostral parts of C5 also followed this fusiform distribution pattern. The dendritic trees of AT and ST motoneurons in caudal C5 were not fusiform but instead had a complex distribution pattern which consisted of dendrites projecting in several directions. Many dendrites projected rostrally and caudally, and in addition, there were major dendritic projections ventrolateral and dorsolateral to the soma. These results indicate that each head of the trapezius muscle is innervated by two structurally dissimilar groups of motoneurons which occupy different spinal segments. Trapezius motoneurons at the same segmental level, regardless of which head of the trapezius muscle they innervated, have similar dendritic trees whose structure differs from those of neighbouring dorsal neck muscle motoneurons in C2, C3, and C4. Thus, the organization of motoneuron dendritic trees appears to be governed by several factors including the muscle innervated by the motoneuron and the transverse and segmental position of the motoneuron's soma.     

单侧坐骨神经完全结扎术后Ⅰ型囊泡膜谷氨酸转运体在大鼠腰髓、背根神经节和结扎远侧端神经干内表达的变化

目的　 研究单侧坐骨神经结扎对大鼠腰 4～ 5脊髓节段和相应的背根神经节 (DRGs)内VGluT1样免疫阳性反应产物表达的影响以及VGluT1通过轴浆流向外周转运的情况。 方法　 采用免疫组织化学方法观察单侧坐骨神经结扎后不同时间内腰 4～ 5脊髓节段、DRGs和结扎部位的近、远侧端神经干内VGLuT1样免疫阳性反应强度的变化。结果　 (1)坐骨神经结扎后第 1和第 2天 ,VGluT1样免疫阳性产物在结扎的同侧腰 4～ 5脊髓节段和相应节段的DRGs内未检测到明显变化 ;但自术后第 4天开始 ,可观察到VGluT1样免疫阳性产物的表达在上述部位逐渐减弱 ;VGluT1样免疫阳性产物表达的降低在上述部位所出现的时间和程度相平行。 (2 )结扎后第 1天即可观察到VGluT1样免疫阳性产物在坐骨神经结扎部位近侧端的表达有所升高 ,但自术后第 4天开始逐渐降低 ;而VGluT1样免疫阳性产物在坐骨神经结扎部位远侧端的表达自结扎后第 1天起就逐渐降低 ,至第 4周时已完全消失。结论　 (1)DRG神经元合成VGluT1,并通过轴浆流将VGLluT1向中枢突和周围突运输 ,故腰髓内部分VGluT1样阳性末梢起源于DRG神经元 ;(2 )外周神经的损伤很易影响到DRG神经元内VGluT1的合成     

Transganglionic regulation of central terminals of dorsal root ganglion cells by nerve growth factor (NGF)

Blockade of axonal transport or transection of the rat sciatic nerve results in transganglionic degenerative atrophy (TDA) of nerve terminals containing fluoride-resistant acid phosphatase (FRAP) in the Rolando substance of the spinal cord. Application of vinblastine (9 micrograms) in a cuff around the sciatic nerve of adult rats blocked the retrograde transport of [125I]NGF in sensory fibers; this amount of vinblastine is identical to the threshold amount that induces TDA. Conversely, application of NGF to the proximal stump of the transected sciatic nerve prevented or delayed the occurrence of TDA as reflected by the maintenance of FRAP in the upper dorsal horn, that otherwise would inevitably disappear following the peripheral nerve lesion. These results suggest that endogenous NGF transported retrogradely in peripheral sensory fibers of the adult rat under normal conditions may be responsible for the regulation of the structural and functional integrity of the central terminals of these FRAP-containing primary sensory neurons and that TDA may be the consequence of the failure of NGF to reach the perikarya of these neurons.     

Sorting of regenerating rat sciatic nerve fibers with target-derived molecules

The functional outcome of microsurgical repair of divided nerves is disappointing since many regenerating axons fail to reach appropriate targets. Sorting of regenerating axons according to target tissue might be used to improve functional regeneration. The aim of the present study is to see if regenerating axons can be sorted into functionally different bundles with target-derived molecules. The proximal stump of the adult rat sciatic nerve was sutured into the inlet of a silicon Y-tube. The two branches of the Y-tube were filled with agarose primed with filtrates prepared from skin and muscle homogenates from the operated rat. The tibial and sural nerves were inserted in the two branches of the Y-tube. Six weeks later the sciatic nerve axons showed vigorous regeneration into both branches. Electron microscopic examination of regenerated nerve segments showed numerous myelinated and unmyelinated axons. The proportion of myelinated axons was significantly larger in the muscle-gel branch than in the skin-gel branch. Retrograde tracing from the nerve regenerates with Fast Blue and Fluoro-Ruby showed that ventral horn neurons at L4-L5 segmental levels were preferentially labeled from the muscle-gel branch. Neurons in corresponding dorsal root ganglia were labeled from both Y-tube branches (no significant numerical difference). A few neurons of both types contained both tracers. Measurements revealed that sensory neurons labeled from the muscle-gel branch were significantly larger (mean perikaryal area 870 microm(2)) than neurons labeled from the skin-gel branch (mean area 580 microm(2)). We conclude that regenerating motor and sensory axons can be sorted with target-derived molecules.     

Galanin and its receptor system promote the repair of injured sciatic nerves in diabetic rats

Various studies have reported that galanin can promote axonal regeneration of dorsal root ganglion neuronsin vitro and inhibit neuropathic pain. However, little is known about its effects on diabetic peripheral neuropathy, andin vivo experimental data are lacking. We hypothesized that repeated applications of exogenous galanin over an extended time frame may also repair nerve damage in diabetic peripheral neuropathy, and relieve pain in vivo. We found that neuropathic pain occurred in streptozotocin-induced diabetic rats and was more severe after sciatic nerve pinch injury at 14 and 28 days than in diabetic sham-operated rats. Treatment with exogenous galanin alleviated the neuropathic pain and promoted sciatic nerve regeneration more effectively in diabetic rats than in non-diabetic rats after sciatic nerve pinch injury. This was accompanied by changes in the levels of endogenous galanin, and its receptors galanin receptor 1 and galanin receptor 2 in the dorsal root ganglia and the spinal dorsal horn when compared with nerve pinch normal rats. Our results show that application of exogenous galanin daily for 28 days can promote the regeneration of injured sciatic nerves, and alleviate neuropathic pain in diabetic rats.     

Safety and efficacy of ranirestat in patients with mild‐to‐moderate diabetic sensorimotor polyneuropathy

We examined the efficacy and safety of ranirestat in patients with diabetic sensorimotor polyneuropathy (DSPN). Patients (18–75 years) with stable type 1/2 diabetes mellitus and DSPN were eligible for this global, double‐blind, phase II/III study ( ClinicalTrials.gov NCT00927914). Patients (n = 800) were randomized 1 : 1 : 1 to placebo, ranirestat 40 mg/day or 80 mg/day (265 : 264 : 271). Change in peroneal motor nerve conduction velocity (PMNCV) from baseline to 24 months was the primary endpoint with a goal improvement vs. placebo ≥1.2 m/s. Other endpoints included symptoms, quality‐of‐life, and safety. Six hundred thirty‐three patients completed the study. The PMNCV difference from placebo was significant at 6, 12, and 18 months in both ranirestat groups, but <1.2 m/s. The mean improvement from baseline at 24 months was +0.49, +0.95, and +0.90 m/s for placebo, ranirestat 40 mg and 80 mg, respectively (NS). The treatment difference vs. placebo reached significance when ranirestat groups were combined in a post hoc analysis (+0.44 m/s; p = 0.0237). There was no effect of ranirestat on safety assessments, secondary or exploratory endpoints vs. placebo. Ranirestat was well tolerated and improved PMNCV, but did not achieve any efficacy endpoints. The absence of PMNCV worsening in the placebo group underscores the challenges of DSPN studies in patients with well‐controlled diabetes.     

Alpha-bungarotoxin binding sites on sensory neurones and their axonal transport in sensory afferents

The autoradiographic localization of [125I]alpha-bungarotoxin binding sites on primary sensory fibres was investigated. Nicotinic alpha-bungarotoxin binding sites were localized to a small sub-population of large dorsal root ganglion cells in the rat, monkey, cat and human dorsal root ganglia. Ligation of the sciatic nerve or dorsal root in the rat resulted in an anterograde accumulation of binding sites proximal to the dorsal root ganglion, and a small retrograde accumulation. Unilateral dorsal root section in the rat produced a loss of toxin binding sites mainly within lamina III of the dorsal horn. These results suggest that nicotinic alpha-bungarotoxin binding sites manufactured in large dorsal root ganglion cell bodies are transported both centrally to the spinal cord and also peripherally.     

Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway

Epalrestat is a noncompetitive and reversible aldose reductase inhibitor used for the treatment of diabetic neuropathy. This study assumed that epalrestat had a protective effect on diabetic peripheral nerve injury by suppressing the expression of aldose reductase in peripheral nerves of diabetes mellitus rats. The high-fat and high-carbohydrate model rats were established by intraperitoneal injection of streptozotocin. Peripheral neuropathy occurred in these rats after sustaining high blood glucose for 8 weeks. At 12 weeks after streptozotocin injection, rats were intragastrically administered epalrestat 100 mg/kg daily for 6 weeks. Transmission electron microscope revealed that the injuries to myelinated nerve fibers, non-myelinated nerve fibers and Schwann cells of rat sciatic nerves had reduced compared to rats without epalrestat administuation. Western blot assay and immunohistochemical results demonstrated that after intervention with epalrestat, the activities of antioxidant enzymes such as superoxide dismutase, catalase and glutathione peroxidase gradually increased, but aldose reductase protein expression gradually diminished. Results confirmed that epalrestat could protect against diabetic peripheral neuropathy by relieving oxidative stress and suppressing the polyol pathway.     

Laminin peptide YIGSR and its receptor regulate sensory axonal response to the chemoattractive guidance cue in the chick embryo

During early development, centrally projecting dorsal root ganglion (DRG) neurons extend their axons toward the dorsal spinal cord. We previously reported the involvement of dorsal spinal cord-derived chemoattraction in this projection (Masuda et al. [ 2007] Neuroreport 18:1645-1649). However, the molecular nature of this attraction is not clear. Here we show that laminin-1 (alpha1beta1gamma1) is expressed strongly along the pathway of DRG axons and that its 67-kDa receptor (67LR) is present on DRG cells. This evidence suggests that laminin-1-67LR signaling may be involved in DRG axonal guidance. By employing culture assays, we show that laminin-1 or the YIGSR peptide, a soluble peptide of the laminin beta1 chain, promotes the DRG axonal response to dorsal spinal cord-derived chemoattraction. By using a function-blocking antibody against 67LR, we show that the anti-67LR antibody blocks the modulation of DRG axonal response by the YIGSR peptide in vitro. Furthermore, the in ovo injection of the anti-67LR antibody inhibits the DRG axonal growth toward the dorsal spinal cord. These results provide evidence that the YIGSR peptide promotes dorsal spinal cord-derived chemoattraction via 67LR to contribute to the formation of the initial trajectories of developing DRG axons.     

Developmental alterations in nociceptive threshold, immunoreactive calcitonin gene-related peptide and substance P, and fluoride-resistant acid phosphatase in neonatally capsaicin-treated rats.

This study examined the effect of neonatal administration of capsaicin on nociceptive threshold and the distribution of calcitonin gene-related peptide (CGRP), substance P (SP), and fluoride-resistant acid phosphatase (FRAP) in the dorsal horn of the spinal cord during the course of development (10 days to 12 weeks of age) in the rat. As early as 10 days of age, CGRP-like immunoreactivity was reduced in laminae I, II, and V, as well as in the bundles of fibers situated dorsal and ventral to the central canal. However, beginning on or about 6 weeks of age, the density of CGRP-like immunoreactivity in the superficial laminae and in the bundles dorsal and ventral to the central canal increased. Moreover, thick, nonvaricose CGRP-like immunoreactive fibers appeared in laminae III and IV. These recurring fibers were of primary afferent origin as demonstrated by their disappearance after multiple, unilateral rhizotomies. A similar age-dependent alteration in the density of FRAP activity was also observed. Although virtually absent at 10 days of age after neonatal administration of capsaicin, the density of FRAP activity increased in lamina II by 8 weeks of age. This activity disappeared after multiple, unilateral rhizotomies, indicating that the FRAP activity that reappeared was of primary afferent origin. Neonatal administration of capsaicin also reduced the density of SP-like immunoreactivity in the dorsal horn as early as 10 days of age, although the density of SP-like immunoreactivity showed some recovery after 6 weeks of age. However, unlike CGRP-like immunoreactivity or FRAP activity, the density of SP-like immunoreactivity in capsaicin-treated rats was not detectably altered by multiple, unilateral rhizotomies, indicating that it originated principally from intrinsic dorsal horn neurons. Age-dependent alterations in both thermal and mechanical, but not chemical, nociceptive thresholds were also observed in these same animals. Thus, tail flick latency, hot plate latency, and paw withdrawal threshold were maximally increased at 6 weeks of age, after which time thresholds declined to vehicle-treated values. In contrast, capsaicin-treated animals were uniformly insensitive to ophthalmic administration of capsaicin. The correspondence between developmental alterations in CGRP-like immunoreactivity or FRAP activity and in thermal and mechanical nociceptive thresholds is suggestive of a role of CGRP- or FRAP-containing primary afferents in thermal and mechanical nociception.     

Comparative study of peripheral neuropathy and nerve regeneration in NOD and ICR diabetic mice

The non-obese diabetic (NOD) mouse was suggested as an adequate model for diabetic autonomic neuropathy. We evaluated sensory-motor neuropathy and nerve regeneration following sciatic nerve crush in NOD males rendered diabetic by multiple low doses of streptozotocin, in comparison with similarly treated Institute for Cancer Research (ICR) mice, a widely used model for type I diabetes. Neurophysiological values for both strains showed a decline in motor and sensory nerve conduction velocity at 7 and 8 weeks after induction of diabetes in the intact hindlimb. However, amplitudes of compound muscle and sensory action potentials (CMAPs and CNAPs) were significantly reduced in NOD but not in ICR diabetic mice. Morphometrical analysis showed myelinated fiber loss in highly hyperglycemic NOD mice, but no significant changes in fiber size. There was a reduction of intraepidermal nerve fibers, more pronounced in NOD than in ICR diabetic mice. Interestingly, aldose reductase and poly(ADP-ribose) polymerase (PARP) activities were increased already at 1 week of hyperglycemia, persisting until the end of the experiment in both strains. Muscle and nerve reinnervation was delayed in diabetic mice following sciatic nerve crush, being more marked in NOD mice. Thus, diabetes of mid-duration induces more severe peripheral neuropathy and slower nerve regeneration in NOD than in ICR mice.     

Glial cell line-derived neurotrophic factor increases calcitonin gene-related peptide immunoreactivity in sensory and motoneurons in vivo

Calcitonin gene-related peptide (CGRP) is expressed at high levels in roughly 50% of spinal sensory neurons and plays a role in peripheral vasodilation as well as nociceptive signalling in the spinal cord. Spinal motoneurons express low levels of CGRP; motoneuronal CGRP is thought to be involved in end-plate plasticity and to have trophic effects on target muscle cells. As both sensory and motoneurons express receptors for glial cell line-derived neurotrophic factor (GDNF) we sought to determine whether CGRP was regulated by GDNF. Rats were treated intrathecally for 1-3 weeks with recombinant human GDNF or nerve growth factor (NGF) (12 microg/day) and dorsal root ganglia and spinal cords were stained for CGRP. The GDNF treatment not only increased CGRP immunoreactivity in both sensory and motoneurons but also resulted in hypertrophy of both populations. By combined in situ hybridization and immunohistochemistry we found that, in the dorsal root ganglia, CGRP was up-regulated specifically in neurons expressing GDNF but not NGF receptors following GDNF treatment. Despite the increase in CGRP in GDNF-treated rats, there was no increase in thermal or mechanical pain sensitivity, while NGF-treated animals showed significant decreases in pain thresholds. In motoneurons, GDNF increased the overall intensity of CGRP immunoreactivity but did not increase the number of immunopositive cells. As GDNF has been shown to promote the regeneration of both sensory and motor axons, and as CGRP appears to be involved in motoneuronal plasticity, we reason that at least some of the regenerative effects of GDNF are mediated through CGRP up-regulation.     

鞘内注射胶质细胞抑制剂对背根神经节压迫大鼠脊髓星形胶质细胞的影响

BACKGROUND： Astrocytes are considered to provide nutritional support in the central nervous system. However, recent studies have confirmed that astrocytes also play an important role in chronic pain.
OBJECTIVE： To investigate the effects of intrathecal injection of fluorocitrate, minocycline or both on astrocyte activation and proliferation in the spinal dorsal horn of compressed dorsal root ganglion in rats.
DESIGN, TIME AND SETTING： The neurology randomized controlled animal study was performed at the Jiangsu Institute of Anesthesia Medicine, from September 2006 to April 2007. MATERIALS： A total of 96 male Sprague Dawley rats, aged 6-8 weeks, were selected for this study. Following intrathecal catheterization, 80 rats underwent steel bar insertion into the L4-5 intervertebral foramina to make a stable compression on the L4-5 posterior root ganglion. Thus rat models of ganglion compression were established. Minocycline and fluorocitrate were purchased from Sigma, USA.
METHODS： A total of 96 rats were randomly and equally divided into six groups. Rat L4, L5 transverse process and intervertebral foramina were exposed in the sham operation group, but without steel bar insertion. The model group did not receive any manipulations. Rats in the phosphate buffered saline （PBS） group were intrathecally injected with 0.01 mmol/L PBS （20 μL）. Rats in the fluorocitrate group were subjected to 1 μmol/L fluorocitrate （20 μL）. Rats in the minocycline group were intrathecally injected with 5 g/L minocycline （20 μL）. Rats in the minocycline and fluorocitrate group received a mixture （20 μL） of 5 g/L minocycline and 1 μmol/L fluorocitrate. Following model establishment, drugs were administered once a day.
MAIN OUTCOME MEASURES： At 7 and 14 days following model induction, glial fibrillary acidic protein expression in the spinal dorsal horn was measured by immunofluorescence microscopy. Six sections with significant glial fibrillary acidic protein -positive expression were obtained to count astrocytes under an inverted microscope.
RESULTS： No significant differences in astrocyte count were detected between the fluorocitrate and model groups. Cell bodies were small with a few processes in the fluorocitrate group, compared with the model group. The astrocyte count decreased significantly in the minocycline group and the minocycline and fluorocitrate group compared with the sham operation, model, PBS and fluorocitrate groups （P 〈 0.01）. The decrease in astrocyte count was mainly found in layers Ⅲ–Ⅳ of the spinal dorsal horn. Cell body volume was smaller and process numbers were fewer in the minocycline group and the minocycline and fluorocitrate group, compared with the model and PBS groups.
CONCLUSION： Fluorocitrate can inhibit astrocyte activation, but does not affect astrocyte proliferation. However, minocycline can inhibit the activation and proliferation of astrocytes.     

Immunocytochemical Localization of trkA Receptors in Chemically Identified Subgroups of Adult Rat Sensory Neurons

Immunocytochemistry has been used to examine the location of trkA, the high-affinity receptor for nerve growth factor, in adult rat dorsal root ganglia, trigeminal ganglia and spinal cord. TrkA immunoreactivity was observed in small and medium sized ganglion cells and in the dorsal horn of the spinal cord. In lumbar L4 and L5 ganglia trkA-immunoreactive cells constitute 40% of dorsal root ganglion cells and range in size from 15 to 45 μm in diameter. Double labelling using markers for various dorsal root ganglion subpopulations revealed that virtually all (92%) trkA-immunoreactive cells express calcitonin gene-related peptide (CGRP) immunoreactivity. In contrast only 4 and 13% of trkA-immunoreactive cells are labelled by the monoclonal antibody LA4 or the lectin Griffonia simplicifolia IB4, markers for small non-peptide-containing cells. Eighteen percent of trkA-immunoreactive cells belong to the 'large light'subpopulation, identified by their strong immunostaining by the neurofilament antibody RT97. TrkA immunoreactivity in the dorsal horn is heaviest in laminae I and II outer, has a similar distribution to CGRP, and is depleted by dorsal rhizotomy. Our results show that trkA-expressing cells in dorsal root ganglia correspond almost exactly with the CGRP, peptide-producing population. The receptor is present not only on cell bodies but also on central terminals. Non-peptide-containing small cells, which constitute 30% of dorsal root ganglion cells, are not trkA-immunoreactive and therefore most probably are functionally independent of nerve growth factor.